The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in a setting of chemotherapy treatment: An assessment of FDA MedWatch database.
V. Garg
No relevant relationships to disclose
Y. Balagula
No relevant relationships to disclose
D. W. Raisch
Research Funding - Abraxis BioScience
M. J. Anadkat
Consultant or Advisory Role - Bristol-Myers Squibb; ImClone Systems
Honoraria - Bristol-Myers Squibb; Eisai
M. E. Lacouture
Consultant or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Genzyme; GlaxoSmithKline; Hana BioSciences; ImClone Systems; Lilly; Onyx; OSI Pharmaceuticals; Pfizer; Roche; Wyeth
Honoraria - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genetic Technologies; Genzyme; GlaxoSmithKline; Hana BioSciences; ImClone Systems; Lilly; Onyx; OSI Pharmaceuticals; Pfizer; Roche; Wyeth
Research Funding - Hana BioSciences; Onyx